Teva 8-K Explained: Q3 Results Filed Under Item 2.02
Teva's November 3 Form 8-K furnishes its third-quarter press release. Here is what the EDGAR filing says about revenue, margins, brands and the 2026 outlook.
- Filer
- Teva Pharmaceutical Industries Ltd.
- Form
- 8-K
- CIK
- 818686
- On EDGAR
- 0001171843-26-007054
An Item 2.02 Form 8-K is the current report a public company files to tell the SEC, and anyone reading EDGAR, that it has released financial results; the numbers themselves usually sit in an attached press release. Teva Pharmaceutical Industries filed one on November 3, 2026, and this EDGAR filing explained below covers what the document is and what its exhibit reports for the third quarter.
What happened
The 8-K itself is short. It reports one event, dated November 3, 2026: Teva issued a press release announcing results for the quarter ended September 30. The release is furnished as Exhibit 99.1, and the cover page confirms that Teva’s ordinary shares trade on the New York Stock Exchange under TEVA. The filing was signed by Chief Financial Officer Eli Kalif.
The substance is in the exhibit. Key figures from it:
- Third-quarter revenue was $4,395 million, down 2% from a year earlier in both U.S. dollars and local currency. Teva attributes the drop mainly to lower generic sales, led by competition for its lenalidomide capsules (a generic version of Revlimid) in the U.S.
- Gross profit margin was 55.5%, against 51.4% a year earlier. Non-GAAP gross margin was 58.7%, up from 55.3%.
- Operating income was $714 million, down from $882 million. Non-GAAP operating income was $1,393 million, a 31.7% margin versus 28.9%.
- Diluted earnings per share were $0.20 (GAAP) and $0.86 (non-GAAP). Net income attributable to Teva was $233 million.
- Free cash flow was $495 million.
Financial expenses of $414 million included a $224 million loss on extinguishment of debt.
The brands behind the guidance
Teva’s three key innovative brands generated about $1.1 billion in the quarter, growing 33% in local currency. The release raises 2026 revenue outlooks for all three.
| Brand | Q3 2026 revenue | Growth (local currency) | New 2026 outlook |
|---|---|---|---|
| AUSTEDO | $751 million | 21% | $2.55-2.65 billion |
| AJOVY | $269 million | 61% | $930-960 million |
| UZEDY | $85 million | 96% | $290-310 million |
For the company as a whole, the 2026 outlook is revenue of $16.7 to $17.0 billion, non-GAAP operating income of $3.8 to $3.9 billion, and free cash flow of $2.1 to $2.4 billion. Teva notes that its non-GAAP operating income and non-GAAP EPS ranges include acquired in-process R&D charges of $0.87 billion and $0.71 per share, respectively.
The release also lists the FDA approval of WELTRUZA in October, the acquisition of BXCL-501 from BioXcel Therapeutics, an FDA-accepted new drug application for ecopipam with an action date expected in the first quarter of 2027, and a discontinued Phase 2 study of emrusolmin after an interim futility analysis.
Where the NYSE listing fits
The release also counts Teva’s direct listing of its ordinary shares on the NYSE among its financial accomplishments for the period, alongside a return to investment-grade credit ratings and the refinancing of roughly $4.9 billion of debt. The release says Moody’s and S&P upgraded Teva to investment grade during the quarter, following an earlier Fitch upgrade. A direct listing places existing shares on an exchange without a new underwritten offering, which is why it reads differently from an IPO.
How it works
Item 2.02 exists so that earnings news reaches the market through a public filing. Material “furnished” under Item 2.02 is treated differently from material “filed”: it is not automatically incorporated into the company’s securities registration statements and carries a different liability standard under Section 18 of the Exchange Act. Companies use the exhibit route so a press release, with its adjusted measures, can be posted without being reworked into a full periodic report.
Key terms
- Non-GAAP: Results adjusted by management to exclude items such as amortization, legal settlements or one-time charges. Reconciliations to GAAP appear in the release.
- Local currency growth: Year-over-year change with exchange-rate effects removed.
- IPR&D: Acquired in-process research and development, a cost recorded when a company buys an unapproved drug candidate.
- Furnished vs. filed: Two legal statuses for information submitted to the SEC.
FAQ
Does the 8-K include the full financial statements? No. The 8-K is a two-item cover document that incorporates the press release; the full statements belong in Teva’s periodic reports.
Why does the revenue fall while profit measures rise? Per the release, the product mix shifted toward higher-margin innovative brands while generic revenue declined.
Prepared with AI assistance from the documents listed in the margin and reviewed under our editorial policy. Not investment advice.